Loomis, Sayles & Company’s Syndax Pharmaceuticals SNDX Stock Holding History

Loomis, Sayles & Company’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.2M	Buy	+923,624	New	+$19.2M	0.03%	255

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Loomis, Sayles & Company's SNDX Position: Q2 2026 in Review

Loomis, Sayles & Company opened a new position in Syndax Pharmaceuticals (SNDX) in Q2 2026: 923,624 shares worth $20.2M. The stake represents 0.03% of the portfolio and ranks #255 among its holdings.

242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Loomis, Sayles & Company held 923,624 shares of Syndax Pharmaceuticals worth $20.2M as of Q2 2026.
Syndax Pharmaceuticals was a new Loomis, Sayles & Company position in Q2 2026.
Syndax Pharmaceuticals made up 0.03% of Loomis, Sayles & Company's portfolio in Q2 2026, its #255 holding.
242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.